- Conditions
- Nonsmall Cell Lung Cancer, Performance Status
- Interventions
- Pembrolizumab, Atezolizumab, Cemiplimab-Rwlc, Carboplatin, Paclitaxel, Nab paclitaxel, Pemetrexed, Cisplatin, Quality of Life Questionnaire, lung cancer-specific (QLQ-LC13), QLQ-C30 Global Health/Quality of Life Questionnaire, COPD Assessment Test and modified Medical Research Council Dyspnea Patient Reported Outcomes, PROMIS and FACT-G Questionnaires, Sleep Disorder Assessments (ISI, Berlin Sleep Questionnaire)
- Drug · Other
- Lead sponsor
- Wake Forest University Health Sciences
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2027
- U.S. locations
- 1
- States / cities
- Winston-Salem, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–4
of 4
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Breast Cancer
- Interventions
- Exercise Recall Patient Reported Outcomes, Health Behavior Questionnaire (HBQ)30 Patient Reported Outcomes, Functional Assessment of Cancer Therapy-General (FACT-G) Patient Reported Outcomes, Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-F) Patient Reported Outcomes, Patient Reported Outcomes PROMIS Cognitive Function (Short Form 8a), Patient Reported Outcomes Functional Assessment of Cancer-Gynecology Oncology Group-Neurotoxicity (FACT/GOG-NTX-12), Patient Reported Outcomes PROMIS, Patient Reported Outcomes FACT-Endocrine Symptoms, Patient Reported Outcomes Penn Arthralgia Aging Survey, Patient Reported Outcomes PRO-CTCAE (patient-reported CTCAE), p16 tumor suppressor gene
- Behavioral · Diagnostic Test
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years and older · Female only
- Enrollment
- 253 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer, Metastasis
- Interventions
- General health survey questionnaires, PROMIS Cancer Function Brief 3D profile questionnaires, FACT-G questionnaires, Godin Leisure-Time Exercise Questionnaire, REAP-S questionnaires
- Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
- Conditions
- Breast Cancer
- Interventions
- Engagement in Physical Activity, Questionnaires
- Behavioral · Other
- Lead sponsor
- UNC Lineberger Comprehensive Cancer Center
- Other
- Eligibility
- 21 Years to 99 Years · Female only
- Enrollment
- 132 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina